DOCSLIB.ORG

Polymyxin B for Injection, USP

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Polymyxin B for Injection, USP 500,000 units per vial | NDC 70860-103-10 ATHENEX AccuraSEETM PACKAGING AND LABELING BIG, BOLD AND BRIGHT — TO HELP YOU SEE IT, SAY IT AND PICK IT RIGHT DIFFERENTIATION IN EVERY LABEL, DESIGNED TO HELP REDUCE MEDICATION ERRORS PLEASE SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING, FOR POLYMYXIN B FOR INJECTION, USP, ENCLOSED. THE NEXT GENERATION OF PHARMACY INNOVATION To order, call 1-855-273-0154 or visit www.Athenexpharma.com Polymyxin B for Injection, USP NDC 70860-103-10 500,000 units per vial DESCRIPTION Glass Vial 500,000 units CONCENTRATION per vial CLOSURE 20 mm UNIT OF SALE 1 vial BAR CODED Yes STORAGE Room Temp. • PRESERVATIVE-FREE • NOT MADE WITH NATURAL RUBBER LATEX • AP-RATED • CHOOSE AccuraSEETM FOR YOUR PHARMACY Our proprietary, differentiated and highly-visible label designs can assist pharmacists in accurate medication selection. With a unique label design for every Athenex product, we’re offering your pharmacy added AccuraSEE. The idea is simple: “So what you see is exactly what you get.” Athenex, AccuraSEE and all label designs are copyright of Athenex. ©2020 Athenex. 000529 To order, call 1-855-273-0154 or visit www.Athenexpharma.com POLYMYXIN B for Injection, USP ASSOCIATED WITH HIGH SERUM LEVELS FOUND IN • Baseline renal function should be done prior to INDICATION AND USAGE PATIENTS WITH IMPAIRED RENAL FUNCTION AND/OR therapy, with frequent monitoring of renal function NEPHROTOXICITY. and blood levels of the drug during parenteral • Polymyxin B sulfate is a drug of choice in the treatment therapy. of infections of the urinary tract, meninges, and THE CONCURRENT OR SEQUENTIAL USE OF OTHER bloodstream caused by susceptible strains of NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH • Avoid concurrent use of a curaiform muscle relaxant Ps. aeruginosa. POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, and other neurotoxic drugs which may precipitate STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTA- respiratory depression. If signs of respiratory paralysis • It may also be used topically and subconjunctivally MICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, appear, respiration should be assisted as required, in the treatment of infections of the eye caused by PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD and the drug discontinued. susceptible strains of Ps. aeruginosa. BE AVOIDED. • As with other antibiotics, use of Polymyxin B for • It may be indicated in serious infections caused by THE NEUROTOXICITY OF POLYMYXIN B SULFATE Injection may result in overgrowth of nonsusceptible susceptible strains of H. influenzae, specifically in CAN RESULT IN RESPIRATORY PARALYSIS FROM organisms, including fungi. meningeal infections, Escherichia coli, specifically NEUROMUSCULAR BLOCKADE, ESPECIALLY WHEN in urinary tract infections, Aerobacter aerogenes , • If superinfection occurs, appropriate therapy should THE DRUG IS GIVEN SOON AFTER ANESTHESIA AND/ specifically in bacteremia and Klebsiella pneumoniae, be instituted. OR MUSCLE RELAXANTS. specifically in bacteremia, when less potentially ADVERSE REACTIONS toxic drugs are ineffective or contraindicated. USAGE IN PREGNANCY: THE SAFETY OF THIS DRUG IN HUMAN PREGNANCY HAS NOT BEEN ESTABLISHED. • Nephrotoxic reactions: Albuminuria, cylinduria, IMPORTANT SAFETY INFORMATION azotemia may occur with use of Polymyxin B for CONTRAINDICATIONS WARNING Injection without any increase in dosage. Polymyxin B for Injection, USP is contraindicated CAUTION: WHEN THIS DRUG IS GIVEN • Neurotoxic reactions: Facial flushing, dizziness, in persons with a prior history of hypersensitivity INTRAMUSCULARLY AND/OR INTRATHECALLY, progressing to ataxia, drowsiness, peripheral reactions to polymyxins. IT SHOULD BE GIVEN ONLY TO HOSPITALIZED paresthesias (circumoral and stocking glove), PATIENTS, SO AS TO PROVIDE CONSTANT WARNINGS apnea due to concurrent use of curaiform muscle SUPERVISION BY A PHYSICIAN. • Clostridium difficile associated diarrhea (CDAD) has relaxant, other neurotoxic drugs or inadvertent overdosage and signs of meningeal irritation with RENAL FUNCTION SHOULD BE CAREFULLY been reported with use of nearly all antibacterial intrathecal administration may occur with use of DETERMINED AND PATIENTS WITH RENAL DAMAGE agents, including Polymyxin B for Injection, and may Polymyxin B for Injection. AND NITROGEN RETENTION SHOULD HAVE REDUCED range in severity from mild diarrhea to fatal colitis. DOSAGE. PATIENTS WITH NEPHROTOXICITY DUE TO • If CDAD is suspected or confirmed ongoing, • Other reactions occasionally reported are drug POLYMYXIN B SULFATE USUALLY SHOW ALBUMINURIA, antibiotic use not directed at C. Difficile may need fever, urticarial rash, pain (severe) at intramuscular CELLULAR CASTS, AND AZOTEMIA. DIMINISHING to be discontinued. injection sites, and thrombophlebitis at intravenous URINE OUTPUT AND A RISING BUN ARE INDICATIONS injection sites. PRECAUTIONS FOR DISCONTINUING THERAPY WITH THIS DRUG. You are encouraged to report negative side • Prescribing polymyxin B in the absence of a NEUROTOXIC REACTIONS MAY BE MANIFESTED BY effects of prescription drugs to the FDA. proven or strongly suspected bacterial infection IRRITABILITY, WEAKNESS, DROWSINESS, ATAXIA, Visit www.fda.gov/medwatch. Or call 1-800-FDA-1088. or a prophylactic indication is unlikely to provide PERIORAL PARESTHESIA, NUMBNESS OF THE EXTREMITIES, a benefit to the patient and increases the risk of Please see full prescribing information for POLYMYXIN AND BLURRING OF VISION. THESE ARE USUALLY the development of drug resistant bacteria. B for Injection, USP..
Recommended publications

  • Susceptibility of Escherichia Coli to 3-Lactam Antibiotics

    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Mar. 1994, p. 494-498 Vol. 38, No. 3 0066-4804/94/$04.00+0 Copyright © 1994, American Society for Microbiology Effect of Hyperproduction of TEM-1 1-Lactamase on In Vitro Susceptibility of Escherichia coli to 3-Lactam Antibiotics PEI-JUN WU,t KEVIN SHANNON,*t AND IAN PHILLIPS Department of Microbiology, United Medical and Dental Schools, St. Thomas' Hospital, London SE1 7EH, United Kingdom Received 21 July 1993/Returned for modification 4 November 1993/Accepted 4 January 1994 The susceptibility of 173 TEM-1-producing isolates of Escherichia coli was assessed by determination of MICs by the agar dilution method. MICs of amoxicillin, mezlocillin, cephaloridine, and, to a smaller extent, amoxicillin-clavulanic acid (but not cephalexin, cefuroxime, cefotaxime, ceftazidime, or imipenem) were higher for isolates that produced large amounts of f8-lactamase than for isolates that produced smaller amounts. The effect of fixed concentrations of clavulanic acid on resistance to amoxicillin was assessed for 34 selected TEM-1-producing isolates. Low concentrations of the inhibitor (0.5 to 1 ,ug/ml) reduced the amoxicillin MICs substantially for almost all the isolates, although the reductions were not sufficient to render any of the isolates amoxicillin susceptible. Higher concentrations of clavulanic acid had progressively greater effects on amoxicillin MICs, but even at 8 ,ug/ml some of the isolates with high P-lactamase activities remained resistant or only moderately susceptible to amoxicillin. All the isolates were inhibited by clavulanic acid (in the absence of amoxicillin) at concentrations of 16 to 32 ,ug/ml. TEM-1 ,-lactamase activity was inhibited in vitro by clavulanic acid, but not totally, with approximately 2% of the initial activity remaining at 2 ,ug/ml and 0.4% remaining at 8 ,guml.
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii

    Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii

    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
  • Swedres-Svarm 2010

    Swedres-Svarm 2010

    SVARM|2010 Swedish Veterinary Antimicrobial Resistance Monitoring Content Swedish Veterinary Antimicrobial Resistance Monitoring 2010 Preface .............................................................................................3 Guidance for readers ........................................................................4 Editors Summary ..........................................................................................5 Björn Bengtsson, Helle Ericsson Unnerstad, Sammanfattning...............................................................................7 Christina Greko, Ulrika Grönlund Andersson and Annica Landén Use of antimicrobials .......................................................................9 Department of Animal Health and Zoonotic bacteria ...........................................................................14 Antimicrobial Strategies, National Veterinary Salmonella ...................................................................................14 Institute (SVA) SE-751 89 Uppsala, Sweden Campylobacter .............................................................................18 Methicillin resistant Staphylococcus aureus (MRSA) ....................19 Authors Highlight: Escherichia coli with ESBL - or transferrable Björn Bengtsson, Helle Ericsson Unnerstad, AmpC-type resistance in broilers .............................................22 Christina Greko, Ulrika Grönlund Andersson and Annica Landén Indicator bacteria ...........................................................................24
  • Conjunctivitis Or Worse?

    Conjunctivitis Or Worse?

    Red Eye in Dogs and CatS: Conjunctivitis or Worse? Tracy Revoir, DVM Senior Manager of Veterinary Support, Dechra Veterinary Products It should come as no surprise that conjunctivitis is Common Causes of Conjunctivitis the most common ophthalmic disorder in dogs and cats. But because the clinical signs of conjunctivitis If you do confirm conjunctivitis, the next step is can mimic those of more serious ophthalmic identifying the cause. If both eyes are affected and diseases (glaucoma and uveitis), it’s important to abnormal clinical signs are apparent in other body confirm your diagnosis. systems, think underlying systemic disease. If only one eye is affected, rule out infection, tear film What are important clues to the severity of the deficiencies, an irritant, anatomical abnormality, condition? With conjunctivitis, the inflammation or deeper ocular disease. should be limited to the conjunctiva. Hyperemic conjunctival vessels are superficial, branching, In dogs, conjunctivitis can result from anatomical and bright red. They are movable over the deeper disorders, irritants, infection (usually bacterial), or episcleral vessels and can be blanched with topical atopy. Most bacterial infections are secondary dilute phenylephrine. With glaucoma and uveitis, the conditions, most often to allergies. In cats, herpes- episcleral vessels are engorged; they are dark red, virus and Chlamydophila felis are the most common deep, straight, and immobile and do not blanch with causes of conjunctivitis. Atopy can also be topical dilute phenylephrine. With conjunctivitis, an issue in cats. the Schirmer tear test and intraocular pressures are normal. And the cornea should be clear and no aqueous flare should be present. The pupil and Addressing the Problem pupillary responses are normal and intraocular structures should be visible.
  • Polymyxin B & Colistin Dosing Tip Sheet

    Polymyxin B & Colistin Dosing Tip Sheet

    Stanford Antimicrobial Safety & Sustainability Program Polymyxin B & Colistin Dosing Tip Sheet What: Polymyxin B is preferred over Colistin (polymyxin E) for infections due to multidrug resistant gram- negative bacilli at Stanford Health Care. SHC formulary restriction criteria – Polymyxin B 1. Infectious Disease Consultation and ID recommendation for use 2. Cystic Fibrosis team SHC formulary restriction criteria – Colistin 1. Treatment of urinary tract infections 2. Inhalation route Why: Polymyxin B and Colistin have the same spectrum of activity. However, Polymyxin B has favorable clinical pharmacologic properties compared to Colistin o Polymyxin B is an active drug, whereas Colistin is administered as the prodrug colistimethate sodium (CMS) and has variable and slow (hours) conversion to the active moiety o Polymyxin B may be less nephrotoxic How: Polymyxin B and Colistin dosing is NOT interchangeable o Polymyxin B is usually dosed by “unit”, not “mg” o Note that with Polymyxin B, each 500,000 units is diluted in 300-500mL: a typical dose may result in 1L of fluid o Consult ID pharmacists if MIC ≥ 2 for alternative dosing strategies Dosing 50-79 30-49 10-29 IHD Route ≥80 mL/min mL/min mL/min mL/min CRRT Polymyxin B No Data; Use actual body IV 7,500 – 12,500 units/kg Q12H Consult ID weight; adjusted body wt for obese pharmacist 2.5 mg/kg 1.5 mg/kg 5 mg/kg/day 1.25–1.9 mg/kg Q24H 1.5 mg/kg Q24-48h Colistin IV in 2-3 divided -OR- Use ideal body Q12H Q36H 2.5 mg/kg weight doses 1.25 mg/kg Q12h Q12-24H Doses expressed in colistin base activity Inhalation 150 mg inhalation Q12H Conversions: Colistimethate sodium 1 mg = ~12,500 units of colistimethate sodium Colistimethate sodium ~2.67 mg = 1 mg of colistin base activity 1 mg colistin base activity (CBA) = 30,000 IU colistin 1 mg polymyxin B = 10,000 IU polymyxin B Orig date: 2/23/2015 LM, EM Stanford Antimicrobial Safety & Sustainability Program References: Micromedex online, accessed 2/17/2016 Nelson, Brian C., et al.
  • Farrukh Javaid Malik

    Farrukh Javaid Malik

    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
  • Belgian Veterinary Surveillance of Antibacterial Consumption National

    Belgian Veterinary Surveillance of Antibacterial Consumption National

    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2020 Publication : 22 June 2021 1 SUMMARY This annual BelVet-SAC report is now published for the 12th time and describes the antimicrobial use (AMU) in animals in Belgium in 2020 and the evolution since 2011. For the third year this report combines sales data (collected at the level of the wholesalers-distributors and the compound feed producers) and usage data (collected at farm level). This allows to dig deeper into AMU at species and farm level in Belgium. With a consumption of 87,6 mg antibacterial compounds/kg biomass an increase of +0.2% is seen in 2020 in comparison to 2019. The increase seen in 2020 is spread over both pharmaceuticals (+0.2%) and antibacterial premixes (+4.0%). This unfortunately marks the end of a successful reduction in antibacterial product sales that was seen over the last 6 years resulting in a cumulative reduction of -40,2% since 2011. The gap seen in the coverage of the sales data with the Sanitel-Med collected usage data increased substantially compared to 2019, meaning continuous efforts need to be taken to ensure completeness of the collected usage data. When looking at the evolution in the number of treatment days (BD100) at the species level, as calculated from the SANITEL- MED use data, use increased in poultry (+5,0%) and veal calves (+1,9%), while it decreased in pigs (-3,1%). However, the numerator data for this indicator remain to be updated for 2020, potentially influencing the reliability of the result.
  • Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP)

    Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP)

    NDA 50-417/S-011 Page 3 NEOSPORIN® Ophthalmic Ointment Sterile (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment, USP) Description: NEOSPORIN Ophthalmic Ointment (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment) is a sterile antimicrobial ointment for ophthalmic use. Each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, bacitracin zinc equivalent to 400 bacitracin units, and white petrolatum, q.s. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 µg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: [Structure] Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: [Structure] Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units per mg. The structural formula is: [Structure] CLINICAL PHARMACOLOGY: A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin. Neomycin is bactericidal for many gram-positive and gram-negative organisms.
  • WO 2010/025328 Al

    WO 2010/025328 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
  • Distinct Penicillin Binding Proteins Involved in the Division

    Distinct Penicillin Binding Proteins Involved in the Division

    Proc. Nat. Acad. Sci. USA Vol. 72, No. 8, pp. 2999- , August 1975 Biochemistry Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12 (P-lactam antibiotics/slab gel electrophoresis/binding protein mutants) BRIAN G. SPRATT Department of Biochemical Sciences, Moffett Laboratories, Princeton University, Princeton, New Jersey 08540 Communicated by Arthur B. Pardee, May 20,1975 ABSTRACT The varied effects of #-lactam antibiotics on ied effects of f3-lactam antibiotics by their relative affinities cell division, cell elongation, and cell shape in E. coil are for three proteins involved in cell division, elongation, and shown to be due to the presence of three essential penicillin binding proteins with distinct roles in these three processes. the maintenance of cell shape. (A) Cell shape: ,-Lactams that specifically result in the pro- duction of ovoid cells bind to penicillin binding protein 2 METHODS (molecular weight 66,000). A mutant has been isolated that The organism used in these studies was E. coil K12 (strain fails to bind ft-lactams to protein 2, and that grows as round cells. (B) Cell division: f-Lactams that specifically inhibit cell KN126). It was grown in Difco Pennassay broth at 370 with division bind preferentially to penicillin binding protein 3 vigorous aeration and harvested at late logarithmic phase. (molecular weight 60,000). A temperature-sensitive cell divi- Mutants B6 and 6-30 were grown in the same medium at sion mutant has been shown to have a thermolabile protein 300. 3. (C) Cell elongation: One ft-lactam that preferentially inhib- Assay of Penicillin Binding Proteins.
  • Appraisal of Multifarious Brands of Cephradine for Their in Vitro Antibacterial Activity Against Varied Microorganisms

    Appraisal of Multifarious Brands of Cephradine for Their in Vitro Antibacterial Activity Against Varied Microorganisms

    Appraisal of multifarious brands of Cephradine for their in vitro antibacterial activity against varied microorganisms Sajid Bashir1, Shamshad Akhtar1, Shahzad Hussain*2, Farnaz Malik2, Sidra Mahmood3, Alia Erum1 and Ume-Ruqiatulain1 1Department of Pharmacy, Sargodha University, Sargodha, Pakistan 2National Institute of Health, Islamabad, Pakistan 3Department of Bioinformatics and Biotechnology, International Islamic University, Islamabad, Pakistan Abstract: The astounding and exceptional growth of generic pharmaceutical Industry in Pakistan has raised certain questions for drug regulatory authorities contemplating their efficacy and quality. The current study focuses on assessing the in-vitro antimicrobial activity of 24 brands of Cephradine 500mg capsules against 4 different strains by employing standardized methods. Disk diffusion method was performed on all brands to look into the susceptibility and resistance patterns. Standard disk of 5µg Cephradine powder were used during evaluation. The zones of inhibitions were ranged from 24-40mm against S. aureus, 24-40mm against E. coli, 20-25mm against K. pneumonia and 19-23mm P. mirabilis. On the basis of mean value, the multinational brands were found to have better zone of inhibitions and were better than local Pharmaceutical companies but ANOVA cooperative study showed that all brands of Cephradine showed similar comparable results. Further investigations by employing MIC method, quality of raw material with special emphasis on the shelf-life, excepients and method of manufacturing will be needed to obtain more authenticated results. The price of National and Multinational brands ranges from Rs.156.00-212.00 for 10 capsules. It is concluded that Public health is at risk because of noticeable growing widespread curse of the manufacture and trade of sub-standard or below par pharmaceuticals.
  • (ESVAC) Web-Based Sales and Animal Population

    (ESVAC) Web-Based Sales and Animal Population

    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.